ARQT
NASDAQArcutis Biotherapeutics Inc.
Website
News25/Ratings12
Price$22.86-3.00 (-11.62%)
2026-01-202026-04-23
News · 26 weeks93-44%
2025-10-262026-04-19
Mix4790d
- Other17(36%)
- Insider14(30%)
- SEC Filings13(28%)
- Earnings2(4%)
- Leadership1(2%)
Latest news
25 items- PRArcutis' ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis GuidelinesStrong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic dermatitis affects approximately 9.6 million children in the United States WESTLAKE VILLAGE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in immuno-dermatology, today announced that ZORYVE® (roflumilast) cream has received a strong recommendation, with high certainty of clinical evidence, in the American Academy of Dermatology (AAD) clinical practice gu
- SECSEC Form S-8 filed by Arcutis Biotherapeutics Inc.S-8 - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)
- SECSEC Form DEFA14A filed by Arcutis Biotherapeutics Inc.DEFA14A - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)
- SECSEC Form DEF 14A filed by Arcutis Biotherapeutics Inc.DEF 14A - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)
- PRArcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026WESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its first quarter 2026 financial results and provide a business update on Wednesday, May 6, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30pm ET. A live webcast of the call and related presentation materials will be available on the "Events" section of the Company's website. A replay of the webcast will be available on the Arcutis investor website following the conferen
- PRThe Credibility Filter Wall Street Uses to Sort Biotech WinnersVANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one of them carried mid or late stage clinical data[1]. That is not a coincidence. The IQVIA Institute's latest annual report found that biopharma dealmaking is now clustering around high value science and companies with credentialed pipelines[2]. It's becoming apparent that smart money is no longer chasing press releases, it's chasing invitations. Conference stage presentations from field defining researchers, peer reviewed journal publications, and stacked regulatory designations have become the fi
- PRPalvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of SalesMr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (NASDAQ:ARQT), where he led U.S. sales efforts for ZORYVE®, a next-generation topical PDE4 inhibitor; previously, he held leadership roles at Incyte (NASDAQ:INCY) supporting the launch of OPZELURA® Mr. Taylor to lead Palvella's U.S. sales organization in preparation for the potential U.S. launch of QTORIN™ rapamycin for microcystic lymphatic malformations, a serious, rare, lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S. WAYNE, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Palvella Ther
- INSIDERSEC Form 4 filed by Welgus Howard G.4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- PRArcutis Management to Present at the 25th Annual Needham Virtual Healthcare ConferenceWESTLAKE VILLAGE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16, 2026. Details for the Company's participation are as follows: Fireside Chat: Tuesday, April 14, 2026 at 11:00 am ET The webcast for this conference may be accessed via the "Events" section of the Company's website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference. About Arcutis
- PRArcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual MeetingInvestigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT programZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four weeksCaregivers reported rapid improvement in itch in as little as 10 minutes in nearly half of infantsResults from additional studies across the ZORYVE portfolio being presented in three poster presentations WESTLAKE VILLAGE, Calif. and DENVER, March 28, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaning
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Arcutis Biotherapeutics Inc.SCHEDULE 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
- PRArcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual MeetingWESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new data from its clinical development program and marketed ZORYVE® (roflumilast) portfolio during the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place March 27-31 in Denver. In an AAD late-breaking podium presentation, the Company will share new efficacy, safety, and tolerability results from its INTEGUMENT-INFANT Phase 2 trial evaluating investigational once-daily ZORYVE cream 0.05% in infants aged 3
- PRArcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric DermatologyZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks of treatmentChildren ages 2-5 who achieved disease clearance and who switched to proactive twice-weekly application sustained disease control for a median duration of ~8 monthsThese results further support the Company's focus on expanding options for pediatric populations WESTLAKE VILLAGE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Pediatric Dermatology published data from the Phase 3 open-label
- PRArcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of GrowthWESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the promotion of Mas Matsuda, JD, currently senior vice president and general counsel, to executive vice president, chief legal officer, and corporate secretary. Mr. Matsuda will continue to lead the Company's legal, compliance, and governance strategy in support of the continued growth of the Company, commercialization of the ZORYVE® (roflumilast) portfolio, and protection of the Company's intellectual property, as well as any corporate transactions. "I am
- INSIDERDirector Leonard Keith R sold $997,195 worth of shares (39,272 units at $25.39) and exercised 39,272 shares at a strike of $8.28 (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDERDirector Welgus Howard G. sold $256,518 worth of shares (10,000 units at $25.65), decreasing direct ownership by 17% to 49,744 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDEROfficer Edwards Larry Todd was granted 30,000 shares and sold $92,846 worth of shares (3,687 units at $25.18), increasing direct ownership by 18% to 175,178 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDEROfficer Watanabe Todd was granted 102,000 shares and sold $940,528 worth of shares (37,349 units at $25.18), increasing direct ownership by 9% to 785,957 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDEROfficer Matsuda Masaru was granted 37,000 shares and sold $313,877 worth of shares (12,058 units at $26.03), increasing direct ownership by 24% to 136,932 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDERSVP Chief Financial Officer Vairavan Latha was granted 27,000 shares and sold $71,844 worth of shares (2,853 units at $25.18), increasing direct ownership by 38% to 87,754 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDEROfficer Burnett Patrick was granted 46,750 shares and sold $158,320 worth of shares (6,287 units at $25.18), increasing direct ownership by 50% to 121,150 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- PRArcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic DermatitisPhase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitisARQ-234 is a potent fusion-protein agonist of the CD200 receptor (CD200R), an immune-regulatory checkpoint involved in maintaining immune balance WESTLAKE VILLAGE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first participant has been enrolled in a Phase 1a/1b, double-blind, randomized, placebo-controlled study, ARQ-234-131, evaluating the s
- SECSEC Form 144 filed by Arcutis Biotherapeutics Inc.144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
- SECSEC Form 144 filed by Arcutis Biotherapeutics Inc.144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
- SECSEC Form 144 filed by Arcutis Biotherapeutics Inc.144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)